Navigation Links
Sangamo BioSciences Reports First Quarter 2012 Financial Results
Date:5/2/2012

n tumor-directed CD8+ T-cells resulting in an enhanced immunotherapeutic product with potent anti-cancer activity coupled with the elimination of graft versus host disease (GvHD) in a mouse model.

Financial Guidance

  • Cash and Investments: Sangamo expects that its cash, cash equivalents and marketable securities will be at least $75 million at the end of 2012, inclusive of the upfront license fee and research funding from Shire but exclusive of funds arising from additional new collaborations or partnerships, or other new sources. 
  • Revenues: Sangamo expects that revenues will be in the range of $14 to $18 million in 2012, inclusive of research funding from Shire.
  • Operating Expenses: Sangamo expects that operating expenses will be in the range of $43 to $47 million for 2012.
  • Conference Call
    Sangamo will host a conference call today, May 2, 2012, at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm.  A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2012. 

    The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 73837943.  For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on May 2, 2012 to 11:59 p.m. ET on May 9, 2012. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
    2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
    3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
    4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
    5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
    6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
    7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
    8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
    9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
    10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
    11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... R.I. , Sept. 2, 2015  Neurotech ... been enrolled in the multicenter Phase 2 clinical ... the long-term treatment of recurrent subfoveal choroidal neovascularization ... NT-503 is a unique vascular endothelial growth factor ... ECT implant. "This landmark proof-of-concept study ...
    (Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
    (Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
    (Date:9/1/2015)... , Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Renshaw 17 th Annual Global Investment Conference sponsored ... September 8-10, 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will ...
    Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
    ... Designation Process and Saves Lives, HARRISBURG, Pa., Aug. ... Web portal that will enable individuals to,sign up as ... driver,s,license or photo ID card is up for renewal ... Web portal, http://www.donatelife-pa.org, will link visitors to ...
    ... - Despite outcome, CEO Mark McDade to resign ... 20 PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ... the company,s chief executive officer (CEO), Mark McDade,found ... breach of,fiduciary duty by McDade to corroborate the ...
    ... Fisher,Scientific Inc. (NYSE: TMO ) announced today ... and chief executive,officer, are adopting stock- trading programs ... the future sale of company stock. Mr.,Dekkers, who ... August,15-17, 2007, has adopted a plan for the ...
    Cached Biology Technology:Web Portal Makes Organ Donation Easy 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2
    (Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
    (Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
    (Date:8/19/2015)... 19, 2015  VOXX International Corporation (Nasdaq: ... into a Definitive Agreement to purchase the assets, ... market leader EyeLock through an acquiring entity.  Upon ... controlling interest in the acquiring entity. The closing ... due diligence.  Expanding on its existing supply chain ...
    Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
    ... that send water surging through swamps and marshes near rivers ... gas emissions from those affected wetlands, according to recent research ... of water through wetlands result in lower average emissions of ... the emissions from wetlands that receive a steady flow of ...
    ... California White Mountain Research Station, U.S. Forest Service ... Climate Research in Western Mountains will host a ... Fairgrounds in Bishop. The conference is entitled "Climate, ... bring together distinguished researchers from a variety of ...
    ... treat breast cancer or prevent its recurrence should think ... report. Genistein, a soy isoflavone that mimics the ... effectiveness of aromatase inhibitors, which are designed to reduce ... in some types of breast cancer. The new ...
    Cached Biology News:Flooding might help lower gas emission from wetlands 2Flooding might help lower gas emission from wetlands 3The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3
    ... GelSpin Kit utilizes a silica based spin filter ... electrophoresis, the desired DNA band is cut from ... spin filter unit. The gel slice is melted ... the DNA is bound to the silica spin ...
    ... to HDAC4 - ChIP Grade HDAC4 ... mammalian histone deacetylases, which consists of 1084 ... highly similar to the deacetylase domain of ... between the nucleus and cytoplasm in a ...
    ... Vector is a derivative of the pAcHLT-A Vector ... fluorescent protein (BFP), followed by a 6xHis tag ... expressed as BFP-6xHis fusion proteins when cloned into ... Stu I, Sac I, Not I, Pst I, ...
    Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
    Biology Products: